Related Experiment Video

Updated: Jan 9, 2026

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant
05:18

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant

Published on: October 6, 2023

1.8K

Advanced Practice Provider-Led Trials in Radiation Oncology: Are We Missing the Opportunity?

Molly K Tate1

  • 1From The University of Texas MD Anderson Cancer Center, Houston, Texas.

Journal of the Advanced Practitioner in Oncology
|December 5, 2025
PubMed

Insights

Advanced practice providers (APPs) are crucial in radiation oncology but face barriers in research leadership. Expanding APP-led research, especially in patient-reported outcomes, requires addressing systemic challenges and fostering mentorship.

Area of Science:

  • Oncology
  • Health Services Research
  • Patient-Reported Outcomes

Background:

  • Advanced practice providers (APPs) are essential members of radiation oncology teams.
  • APPs are currently underrepresented in clinical research leadership roles.
  • Their proximity to patient care offers unique insights for research.

Purpose of the Study:

  • To explore barriers and opportunities for APP-led research in radiation oncology.
  • To identify strategic pathways for increasing APP involvement in clinical research.
  • To focus on patient-reported outcomes (PROs) and health services research.

Main Methods:

  • Literature review and analysis of systemic challenges.
  • Exploration of national initiatives supporting research.
  • Discussion of strategic pathways for institutional support.

Main Results:

  • Key barriers include limited protected research time, inconsistent credentialing, and lack of mentorship.
  • National initiatives like PROTEUS provide tools and funding for PRO integration.
  • Opportunities exist to align APP expertise with research priorities.

Conclusions:

  • Advancing APP-led research is vital for inclusive and patient-centered radiation oncology research.
  • Addressing systemic barriers and providing mentorship are critical steps.
  • Supporting APPs in research leadership enhances innovation and care quality.

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.9K
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

16.1K

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.1K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K